Strategic Partnership Recent partnership with ADVANZ PHARMA indicates openness to collaboration and potential co-development or distribution opportunities for modern biosimilars and expanded access programs.

Leadership Updates New CEO and Board appointments signal strategic leadership changes that could drive M&A activity, geographic expansion, and a renewed focus on scale, efficiency, and international partnerships.

Allergen portfolio Leading position in development and manufacturing of modified allergen extracts presents cross-sell potential to adjacent respiratory and food allergy markets, including diagnostics and therapy optimization.

Security & Resilience Past ransomware incident followed by governance changes suggests a buyer or partner emphasis on robust cybersecurity, resilient supply chains, and high-quality GMP-compliant manufacturing for sensitive biologics.

Growth Readiness Revenue range and sizeable workforce indicate capacity for expanded production, CDMO partnerships, or contract manufacturing for allergen extracts and biosimilars, appealing to large-scale distributors and mid-sized pharma.